Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077664 | 1.00 | CXCR2 (0.70) | CXCR2HTTSMN1; SMN2 | |
| SCHEMBL10077648 | 0.85 | CXCR2 (0.73) | CXCR2HTTSMN1; SMN2 | |
| SCHEMBL334259 | 0.85 | CXCR2 (0.73) | CXCR2HTTSMN1; SMN2 | |
| SCHEMBL334857 | 0.84 | CXCR2 (0.73) | CXCR2 | |
| SCHEMBL1199477 | 0.83 | CXCR2 (1.00) | CXCR2 | |
| SCHEMBL10077636 | 0.81 | CXCR2 (0.64) | CXCR2HTTSMN1; SMN2 | |
| SCHEMBL334529 | 0.81 | CXCR2 (0.64) | CXCR2HTTSMN1; SMN2 | |
| SCHEMBL14385918 | 0.81 | CXCR2 (0.56) | CXCR2HTTSMN1; SMN2 | |
| SCHEMBL334692 | 0.79 | CXCR2 (0.61) | CXCR2 | |
| SCHEMBL1198248 | 0.77 | CXCR2 (1.00) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298810-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2009-12-03 | — | — | US | claimed |
| US-8097626-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090298810-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298810-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR2 6/4885HTT 3810/4885SMN1; SMN2 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.